GlassScriptPhysician profile
Chuma Obineme
NPI 1386175552
$11,225.94
in general payments reported to CMS, 2019-2025
25 companies · $8,870 in 2025
The $8,870 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,039 · 2024: $1,317 · 2025: $8,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $3,297 · Travel and Lodging: $712 · Education: $17.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $3,296.97 |
| Travel and Lodging | $711.70 |
| Education | $17.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,929.28 | 2023-2025 | |
| Abbvie INC. | $664.13 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $248.77 | 2024-2025 | Voquezna |
| Inari Medical, INC. | $194.33 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lilly USA, LLC | $158.42 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $133.68 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $122.49 | 2025 | Tremfya |
| Pfizer INC. | $109.22 | 2023-2024 | |
| Medtronic, INC. | $94.55 | 2023 | Endoflip |
| Janssen Biotech, INC. | $88.03 | 2023-2025 | Stelara, Tremfya |
| Atmo Biosciences INC | $82.62 | 2025 | Atmo Biosciences |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Daiichi Sankyo INC. | $48.60 | 2024-2025 | Injectafer |
| Celgene Corporation | $44.09 | 2023-2024 | Zeposia |
| Neuraxis, INC. | $33.29 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $30.45 | 2024 | Axonics |
| Ferring Pharmaceuticals INC. | $26.56 | 2024 | Rebyota |
| Organon LLC | $23.91 | 2023 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $19.26 | 2024 | Resmetirom |
| Shield Therapeutics INC | $18.27 | 2024 | |
| Celltrion USA INC. | $17.27 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $16.75 | 2024 | |
| Aimmune Therapeutics, INC. | $16.39 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $15.18 | 2024 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chuma Obineme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.